Reference
1. Antzelevitch C, Yan GX, Ackerman MJ, Borggrefe M, Corrado D, Guo J, et al. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Heart Rhythm. 2016;13(10):e295-324.
2. Brugada J, Campuzano O, Arbelo E, Sarquella-Brugada G, Brugada R. Present Status of Brugada Syndrome: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(9):1046-59.
3. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation. 2010;121(5):635-43.
4. Vutthikraivit W, Rattanawong P, Putthapiban P, Sukhumthammarat W, Vathesatogkit P, Ngarmukos T, et al. Worldwide Prevalence of Brugada Syndrome: A Systematic Review and Meta-Analysis. Acta Cardiol Sin. 2018;34(3):267-77.
5. Rattanawong P, Ngarmukos T, Chung EH, Vutthikraivit W, Putthapiban P, Sukhumthammarat W, et al. Prevalence of Brugada ECG Pattern in Thailand From a Population-Based Cohort Study. J Am Coll Cardiol. 2017;69(10):1355-6.
6. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932-63.
7. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-5.
8. Kuriachan VP, Sumner GL, Mitchell LB. Sudden cardiac death. Curr Probl Cardiol. 2015;40(4):133-200.
9. Freeman MF, Tukey JW. Transformations Related to the Angular and the Square Root. Ann Math Statist. 1950;21(4):607-11.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
11. Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29(29):3046-67.
12. Debray TPA, Moons KGM, Riley RD. Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: A comparison of new and existing tests. Research synthesis methods. 2018;9(1):41-50.
13. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37(5):1148-57.
14. Andorin A, Behr ER, Denjoy I, Crotti L, Dagradi F, Jesel L, et al. Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. Heart Rhythm. 2016;13(6):1274-82.
15. Benito B, Sarkozy A, Mont L, Henkens S, Berruezo A, Tamborero D, et al. Gender differences in clinical manifestations of Brugada syndrome. J Am Coll Cardiol. 2008;52(19):1567-73.
16. Chinushi M, Komura S, Izumi D, Furushima H, Tanabe Y, Washizuka T, et al. Incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome. Pacing Clin Electrophysiol. 2007;30(5):662-71.
17. Delise P, Allocca G, Marras E, Giustetto C, Gaita F, Sciarra L, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J. 2011;32(2):169-76.
18. Giustetto C, Drago S, Demarchi PG, Dalmasso P, Bianchi F, Masi AS, et al. Risk stratification of the patients with Brugada type electrocardiogram: a community-based prospective study. Europace. 2009;11(4):507-13.
19. Hernandez-Ojeda J, Arbelo E, Borras R, Berne P, Tolosana JM, Gomez-Juanatey A, et al. Patients With Brugada Syndrome and Implanted Cardioverter-Defibrillators: Long-Term Follow-Up. J Am Coll Cardiol. 2017;70(16):1991-2002.
20. Hiraoka M, Takagi M, Yokoyama Y, Sekiguchi Y, Aihara N, Aonuma K, et al. Prognosis and risk stratification of young adults with Brugada syndrome. J Electrocardiol. 2013;46(4):279-83.
21. Kamakura S, Ohe T, Nakazawa K, Aizawa Y, Shimizu A, Horie M, et al. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3. Circ Arrhythm Electrophysiol. 2009;2(5):495-503.
22. Kharazi A, Emkanjoo Z, Alizadeh A, Nikoo MH, Jorat MV, Sadr-Ameli MA. Mid-term follow-up of patients with Brugada syndrome following a cardioverter defibrillator implantation: a single center experience. Indian Pacing Electrophysiol J. 2007;7(1):33-9.
23. Ohkubo K, Watanabe I, Takagi Y, Okumura Y, Ashino S, Kofune M, et al. Electrocardiographic and electrophysiologic characteristics in patients with Brugada type electrocardiogram and inducible ventricular fibrillation: single center experience. Circ J. 2007;71(9):1437-41.
24. Ouali S, Boughzela E, Haggui A, Haouala H, Battikh K, Ben Ameur Y, et al. Clinical and electrophysiological profile of Brugada syndrome in the Tunisian population. Pacing Clin Electrophysiol. 2011;34(1):47-53.
25. Priori SG, Gasparini M, Napolitano C, Della Bella P, Ottonelli AG, Sassone B, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. 2012;59(1):37-45.
26. Schukro C, Berger T, Stix G, Pezawas T, Kastner J, Hintringer F, et al. Regional prevalence and clinical benefit of implantable cardioverter defibrillators in Brugada syndrome. Int J Cardiol. 2010;144(2):191-4.
27. Conte G, Sieira J, Sarkozy A, de Asmundis C, Di Giovanni G, Chierchia GB, et al. Life-threatening ventricular arrhythmias during ajmaline challenge in patients with Brugada syndrome: incidence, clinical features, and prognosis. Heart Rhythm. 2013;10(12):1869-74.
28. Sieira J, Conte G, Ciconte G, Chierchia GB, Casado-Arroyo R, Baltogiannis G, et al. A score model to predict risk of events in patients with Brugada Syndrome. Eur Heart J. 2017;38(22):1756-63.
29. Son MK, Byeon K, Park SJ, Kim JS, Nam GB, Choi KJ, et al. Prognosis after implantation of cardioverter-defibrillators in Korean patients with Brugada syndrome. Yonsei Med J. 2014;55(1):37-45.
30. Ueoka A, Morita H, Watanabe A, Morimoto Y, Kawada S, Tachibana M, et al. Prognostic Significance of the Sodium Channel Blocker Test in Patients With Brugada Syndrome. J Am Heart Assoc. 2018;7(10).
31. Sieira J, Brugada P. Management of Brugada Syndrome 2016: Should All High Risk Patients Receive an ICD? All High-Risk Patients Should Receive an Implantable Cardiac Defibrillator. Circulation Arrhythmia and electrophysiology. 2016;9(11).
32. Casado-Arroyo R, Berne P, Rao JY, Rodriguez-Manero M, Levinstein M, Conte G, et al. Long-Term Trends in Newly Diagnosed Brugada Syndrome: Implications for Risk Stratification. Journal of the American College of Cardiology. 2016;68(6):614-23.
33. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol. 1996;27(5):1061-70.
34. Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101(5):510-5.
35. Cheung CC, Mellor G, Deyell MW, Ensam B, Batchvarov V, Papadakis M, et al. Comparison of Ajmaline and Procainamide Provocation Tests in the Diagnosis of Brugada Syndrome. JACC Clinical electrophysiology. 2019;5(4):504-12.
36. Sacher F, Probst V, Maury P, Babuty D, Mansourati J, Komatsu Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2. Circulation. 2013;128(16):1739-47.
37. Dereci A, Yap SC, Schinkel AFL. Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Implantation in Patients With Brugada Syndrome. JACC Clin Electrophysiol. 2019;5(2):141-8.